Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Addressing the threat of drug-resistant gonorrhea
Filetype[PDF-65.01 KB]

  • Description:
    Antibiotic resistance is threatening the effectiveness of gonorrhea treatment in the United States. Gonorrhea is one of the most common sexually transmitted diseases (STDs), with more than 800,000 infections estimated to occur in the United States each year. Left untreated, it can cause serious health problems, particularly for women, including chronic pelvic pain, life-threatening ectopic pregnancy, and even infertility. And while medication for gonorrhea has been available for decades, the bacteria has grown resistant to nearly every drug ever used to treat it. In response to the ongoing threat of drug resistance, CDC has repeatedly revised its gonorrhea treatment guidelines to phase out the use of antibiotics that have become less effective in treating the infection. In the United States today, only one recommended treatment option remains – a combination of the antibiotics azithromycin and ceftriaxone. CDC encourages providers to adhere to the recommended dual therapy treatment guidelines, and urges researchers in the public and private sectors to step up efforts to develop new treatments for this common but potentially serious STD. It’s also essential to maintain systems and services across the United States to prevent, diagnose and treat gonorrhea. Effective diagnosis and treatment are essential to protect individual health and stop the spread of infection, including resistant strains. drug-resistant-gonorrhea.pdf
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: